NL-OMON26844RecruitingNot Applicable
GAP-trial: General Anesthesia exposure and neurodevelopmental outcome in Pediatric
Emma Children’s Hospital, Amsterdam UMC.0 sites70 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
Inclusion Criteria
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria: age 12 months (± four weeks) with a history of general anesthesia exposure (patient group) or without a history of general anesthesia (healthy controls)
Exclusion Criteria
- •Children with comorbid conditions affecting structure and/or function of the central nervous system (e.g. premature birth) will be excluded from participation in this study.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Ensayo clínico para evaluar el efecto sobre la grasa subcutánea del cambio de EFV por LPV/r en pacientes infectados por VIH que desarrollaron lipoatrofia que sigue siendo clínicamente evidente a pesar del tratamiento con efavirenz y una combinación a dosis fija de análogos de nucleósidos no timidínicos.EUCTR2009-010611-33-ESFundació clinic per a la Recerca biomèdica
Not yet recruiting
Phase 2
clinical study on the effect of Gudapippali Ghruta and Shatavari Ghruta in the management of Parinama shoola(Acid Peptic Disorders ) and to study the role of H.Pylori in its manifastation.â??CTRI/2017/08/009316Rajiv Gandhi University of Health Sciences
Not yet recruiting
Not Applicable
A human pilot study to investigate the effect of daily consumption of gold kiwifruit for 2 weeks on transcriptomic changes in buccal epithelial cells and blood in healthy males.ACTRN12620001359921Plant & Food Research6
Active, not recruiting
Phase 1
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non Hodgkin’s LymphomaRelapsed or Refractory, Follicular Non-Hodgkin’s LymphomaMedDRA version: 8.1Level: LLTClassification code 10029627Term: Non-Hodgkin's lymphoma unspecified histology intermediate grade refractoryEUCTR2005-003836-22-SKBiogen Idec Ltd.700
Active, not recruiting
Phase 1
A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non Hodgkin’s LymphomaRelapsed or Refractory, Follicular Non-Hodgkin’s LymphomaMedDRA version: 8.1Level: LLTClassification code 10029627Term: Non-Hodgkin's lymphoma unspecified histology intermediate grade refractoryEUCTR2005-003836-22-GBBiogen Idec Ltd.742